Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Key Highlights
- ➤Robin Swartz appointed President effective immediately, succeeding CEO in Q1 2027
- ➤VY1706 initial acute safety data expected in Q1 2027, pending enrollment
- ➤Alfred W. Sandrock to remain CEO through VY1706 safety data
- ➤Sandrock will continue strategic guidance as a Voyager Board member
Expert Statements
Michael Higgins, Chairman of Voyager’s Board
“Robin brings a deep understanding of Voyager as well as extensive experience spanning development, operations, business strategy, and commercialization”
Michael Higgins, Chairman of Voyager’s Board
“Her strategic vision, commitment to patients, and proven ability to consistently deliver results are why the Board unanimously selected her as the most qualified candidate to lead Voyager’s advancement of its increasingly development-stage pipeline.”
Robin Swartz, President and incoming CEO of Voyager Therapeutics
“I am honored by the Board’s confidence in my ability to lead Voyager into its next chapter and to build on the foundation of a visionary like Al, who is widely regarded as a leading neurotherapeutics drug developer”
Robin Swartz, President and incoming CEO of Voyager Therapeutics
“Over the last five years, Voyager has established a differentiated platform and pipeline with the potential to unlock life-changing treatments for neurological diseases; our focus now is on translating that potential into medicines for patients and I am excited to lead Voyager as we advance to this next stage.”
Alfred W. Sandrock, Jr., CEO of Voyager Therapeutics
“I joined Voyager because I believe its scientists have developed an unparallelled gene therapy approach to overcome one of the most significant challenges in neurotherapeutics – crossing the blood-brain barrier, and I could not be prouder of our progress on this front”
Alfred W. Sandrock, Jr., CEO of Voyager Therapeutics
“I am committed to seeing Voyager obtain acute safety data with our lead gene therapy product candidate, VY1706.”
Alfred W. Sandrock, Jr., CEO of Voyager Therapeutics
“I believe that milestone represents an important point in Voyager’s evolution and an ideal time for Robin to assume leadership.”
Alfred W. Sandrock, Jr., CEO of Voyager Therapeutics
“She has been my partner in driving corporate strategy for the past five years and is an exceptional and widely respected leader within our organization.”
Alfred W. Sandrock, Jr., CEO of Voyager Therapeutics
“I look forward to continuing to support Robin and Voyager from the Board.”
George Scangos, Chairman of the Nominating and Governance Committee for the Voyager Board of Directors
“On behalf of Voyager’s Board, we are deeply grateful to Al for his leadership and for the transformation of Voyager.”
George Scangos, Chairman of the Nominating and Governance Committee for the Voyager Board of Directors
“During the past five years, he has prioritized and advanced programs that have the potential to benefit millions of patients with neurodegenerative diseases.”
George Scangos, Chairman of the Nominating and Governance Committee for the Voyager Board of Directors
“He has entered into partnerships to help move those programs forward and to provide funding for Voyager’s internal programs.”
George Scangos, Chairman of the Nominating and Governance Committee for the Voyager Board of Directors
“Importantly, he has shepherded Voyager’s signature capsid platform into the clinical stage with human acute safety data expected in early 2027.”
George Scangos, Chairman of the Nominating and Governance Committee for the Voyager Board of Directors
“We are fortunate that Voyager will continue to benefit from his experience and perspective as a member of the Board.”
- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 -
- Dr. Sandrock expected to remain CEO through initial acute safety data with VY1706, anticipated in Q1 2027 pending enrollment, and to subsequently continue as a member of Voyager’s Board of Directors -
Get started
Create a free account to read the full story.